指南解读

2023年美国国立综合癌症网络(NCCN)《骨髓增生异常综合征临床实践指南》(第1版)解读

展开
  • 上海交通大学医学院附属第六人民医院血液科,上海 200233

收稿日期: 2022-11-15

  网络出版日期: 2023-08-31

基金资助

国家自然科学基金(82070129);SHDC临床研究计划(SHDC 2020 CR 6004);优秀医学学科带头人项目(2019LJ16)

Interpretation of clinical practice guidelines for myelodysplastic syndrome (version 1, 2023) of National Comprehensive Cancer Nerwork(NCCN)

Expand
  • Department of Hematology, Shanghai Sixth people’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China

Received date: 2022-11-15

  Online published: 2023-08-31

摘要

骨髓增生异常综合征(myelodysplastic syndrome,MDS)是血液系统中较为常见的一组髓系恶性克隆性疾病。不同分型的MDS患者,其临床表现及自然病程各异,加上历史上不同分型系统及版本的迭代,对其诊断、分型及治疗方案选择造成了一定困扰。美国国立综合癌症网络(National Comprehensive Cancer Network,NCCN)于2022年9月发布了2023年第1版NCCN的MDS临床实践指南。该指南是基于高级别循证医学证据和最新研究进展而制定的MDS临床实践标准,其受到全球临床医师的广泛关注。目前,我国许多临床医师对MDS的认识不足,与国际MDS诊断及治疗水平间仍存在一定的差距。本文将对该指南发布内容进行解读,并与既往相关指南比较。

本文引用格式

宋陆茜, 常春康 . 2023年美国国立综合癌症网络(NCCN)《骨髓增生异常综合征临床实践指南》(第1版)解读[J]. 诊断学理论与实践, 2023 , 22(02) : 116 -120 . DOI: 10.16150/j.1671-2870.2023.02.002

Abstract

Myelodysplastic syndrome (MDS) is a diverse and common group of myeloid malignant clonal diseases in the hematologic system, with different classification and grouping, clinical manifestations and natural course, and the iteration of different classification systems and versions in history, resulting distress in the correct diagnosis, classification and treatment options. The National Comprehensive Cancer Network (NCCN) released the first version (2023) of Clinical Practice Guidelines for MDS in September 2022. The guideline is based on the clinical practice and standards of high-level evidence and the latest research progress, and its attracts wide attention from clinicians worldwide. Currently, many clinicians in China have insufficient understanding of MDS, and there is still a certain gap with the international diagnosis and treatment level of MDS. This paper interprets the content of the new guidelines, and compares it with the previous guidelines, in order to provide a reference for the standardized diagnosis and treatment of MDS at the current stage in China.

参考文献

[1] CAZZOLA M. Myelodysplastic Syndromes[J]. N Engl J Med, 2020, 383(14):1358-1374.
[2] NCCN. Clinical Practice Guidelines in Oncology. Myelodysplastic syndromes, version1. 2023[R/OL]. 2023[2022-11-21]. https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf.
[3] KHOURY J D, SOLARY E, ABLA O, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms[J]. Leukemia, 2022, 36(7):1703-1719.
[4] ARBER D A, ORAZI A, HASSERJIAN R P, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data[J]. Blood, 2022, 140(11):1200-1228.
[5] BERNARD E, TUECHLER H, GREENBERG P L, et al. Molecular International Prognostic Scoring System for myelodysplastic syndromes[J/OL]. NEJM Evid, 2022 [2022-11-21]. https://evidence.nejm.org/doi/10.1056/EVIDoa2200008.
[6] GREENBERG P L, TUECHLER H, SCHANZ J, et al. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes[J]. Blood, 2016, 128(16):2096-2097.
[7] DELLA PORTA M G, TRAVAGLINO E, BOVERI E, et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes[J]. Leukemia, 2015, 29(1):66-75.
[8] CHEN X, FROMM J R, NARESH K N. "Blasts" in myeloid neoplasms - how do we define blasts and how do we incorporate them into diagnostic schema moving forward?[J]. Leukemia, 2022, 36(2):327-332.
[9] ESTEY E, HASSERJIAN R P, D?HNER H. Distinguis-hing AML from MDS: a fixed blast percentage may no longer be optimal[J]. Blood, 2022, 139(3):323-332.
[10] GREENBERG P L, TUECHLER H, SCHANZ J, et al. Revised international prognostic scoring system for mye-lodysplastic syndromes[J]. Blood, 2012, 120(12):2454-2465.
[11] MARGOLSKEE E, HASSERJIAN R P, HASSANE D, et al. Myelodysplastic syndrome, unclassifiable (MDS-U) with 1% blasts is a distinct subgroup of MDS-U with a poor prognosis[J]. Am J Clin Pathol, 2017, 148(1):49-57.
[12] BERSANELLI M, TRAVAGLINO E, MEGGENDORFER M, et al. Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes[J]. J Clin Oncol, 2021, 39(11):1223-1233.
文章导航

/